Crainio

Crainio operates in the neurotechnology and medical-device segment focused on non-invasive intracranial pressure assessment. Its stated differentiation is the combination of a forehead-mounted optical sensor, low-power near-infrared light, signal processing and a simple color-based output. This contrasts with invasive monitoring approaches that require placement of an intracranial sensor and are generally limited to selected hospital settings and critically ill patients. The proposed workflow also differs from systems that depend on continuous numeric interpretation, positioning Crainio’s indicator as a rapid bedside screening or escalation aid. The target use cases—severe traumatic brain injury, emergency care, wards, operating theatres and transfers—suggest an emphasis on portability and monitoring continuity across care settings. The 40-patient first-in-human pilot provides an early clinical validation signal, but there is insufficient information on sensitivity, specificity, regulatory clearance, reimbursement or deployment scale. Crainio’s market position should therefore be viewed as an early-stage, clinically oriented device proposition rather than an established commercial category leader.

Crainio’s trajectory is defined primarily by technology development and early clinical validation rather than by disclosed financing, hiring or commercial expansion. The company has progressed from a concept centered on non-invasive intracranial pressure monitoring to a described system combining a forehead-mounted single-use patch, near-infrared optical sensing and signal-processing algorithms. A first-in-human pilot involving 40 severe traumatic brain injury patients represents the clearest reported inflection point, indicating movement toward clinical evidence generation. The intended deployment across emergency departments, wards, operating theatres and patient transfers also reflects an effort to extend intracranial hypertension monitoring beyond settings where invasive devices are practical. There are no disclosed funding rounds, valuation events, product launch dates, employee growth figures or partnership announcements in the available profile. The recorded team size of approximately one to ten employees suggests that the organization remains small, while its active operating status indicates ongoing activity. Future growth will likely depend on additional clinical validation, regulatory authorization, manufacturing readiness and adoption by hospitals.